Agendia

OverviewSuggest Edit

Agendia offers discovery, development, marketing, and commercialization of genomic-based diagnostic products to improve the quality of life for cancer patients by providing healthcare professionals with critical information to enable personalized treatment. It offers Symphony suite of molecular diagnostic breast cancer tests, such as TargetPrint, a microarray-based gene expression assay, which offers a quantitative assessment of the patient’s level of estrogen receptor, progesterone receptor, and HER2/neu gene within breast cancer tumor; and MammaPrint, a IVDMIA gene expression breast cancer assay that provides physicians with the ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery.

TypePrivate
Founded2003
HQIrvine, CA, US
Websiteagendia.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Jul 2021)236
Job Openings18
Cybersecurity ratingAMore

Key People/Management at Agendia

Mark R. Straley

Mark R. Straley

Chief Executive Officer
Kurt Becker

Kurt Becker

Chief Operating Officer
Brian Dow

Brian Dow

Chief Financial Officer
William Audeh

William Audeh

Chief Medical Officer
Wendy Blosser

Wendy Blosser

Chief Commercial Officer
Laura van 't Veer

Laura van 't Veer

Chief Research Officer and Co‑founder
Show more

Agendia Office Locations

Agendia has offices in Irvine and Amsterdam
Irvine, CA, US (HQ)
22 Morgan
Amsterdam, NL
Radarweg 60
Show all (2)

Agendia Financials and Metrics

Summary Metrics

Founding Date

2003

Agendia total Funding

$122 m

Agendia latest funding size

$65 m

Time since last funding

9 years ago

Agendia investors

Agendia's latest funding round in March 2012 was reported to be $65 m. In total, Agendia has raised $122 m
Show all financial metrics

Agendia Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Agendia Online and Social Media Presence

Embed Graph

Agendia News and Updates

Agendia to Participate in Stifel 2020 Virtual Healthcare Conference

IRVINE, Calif., Oct. 15, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Stifel Virtual Healthcare Conference, which takes place November 16-18, 2020. Agendia Chief Executive Mark Straley will...

Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany

IRVINE, Calif., Oct. 6, 2020 /PRNewswire/ -- Agendia Inc., a world leader in precision oncology for breast cancer, announced today the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping tests, provided by PathoNext lab...

Agendia présente de nouvelles données démontrant l'utilité clinique de MammaPrint et BluePrint lors de l'événement virtuel de la Conférence européenne sur le cancer du sein 2020

Présentations incluant les données de l'étude MINDACT de suivi et des évaluations sur l'utilisation de MammaPrint pour guider les décisions de traitement concernant les cancers lobulaires et pour les cancers du sein détectés par dépistage par rapport aux cancers du sein détectés par...

Agendia presenta nuevos datos que demuestran la utilidad clínica de MammaPrint y BluePrint

Agendia presenta nuevos datos que demuestran la utilidad clínica de MammaPrint y BluePrint en el evento virtual de la Conferencia Europea sobre el Cáncer de Mama 2020 Las presentaciones incluyen datos de seguimiento del estudio MINDACT y evaluaciones sobre el uso de MammaPrint para guiar...

Agendia Presents New Data Demonstrating MammaPrint's Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress

IRVINE, Calif., Sept. 17, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 showing that MammaPrint's Ultra-Low risk threshold can identify...

Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology

IRVINE, Calif., July 27, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the publication of MINDACT trial data in the July 27 issue of Communications Biology, a Nature Publishers Journal. In the largest data set seen to date, the...
Show more

Agendia Blogs

Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint

PUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Kaklamani2, Yuan Yuan3, Julie Barone4, Sami Diab5, Jennifer A. Crozier6, Pat W. Whitworth7, Karen L. Tedesco8, Robert Maganini9, Rakhshanda Layeequr Rahman10, Carlos A. Encarnacion11, Josien Haan12, Amy M. Truitt12, Andrea Menicucci12,…

Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients ≤ 50 years and > 50 years

PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Marks2, Nina D’Abreo2, Sami Diab3, Vijayakrishna K. Gadi4, Midas M. Kuilman5, Andrea Menicucci6, Amy M. Truitt6, Shiyu Wang6, Patricia Dauer6, William Audeh6, FLEX Investigators’ Group8 Background Recent prospective clinical trials have demons…

Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer

PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Kanter Marks1,2, Heather M. Kling3, Josien Haan4, William Audeh3, FLEX Investigators Group5 Background Lymphovascular invasion (LVI), the passage of carcinoma cells through lymphatic and blood vessels, is an important early …

Agendia’s MammaPrint Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial

MammaPrint was the only test to predict significant 36% and 52% reductions in DFS and BCFI events, respectively, for patients treated with extended endocrine therapy MammaPrint testing for endocrine management decisions will be available in the US and the rest of the world as early as Q3 2021 June 0…

Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers

Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk June 05, 2021 08:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, I…

Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations

Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry Separate abstract shows MammaPrint reclas…
Show more

Agendia Frequently Asked Questions

  • When was Agendia founded?

    Agendia was founded in 2003.

  • Who are Agendia key executives?

    Agendia's key executives are Mark R. Straley, Kurt Becker and Brian Dow.

  • How many employees does Agendia have?

    Agendia has 236 employees.

  • Who are Agendia competitors?

    Competitors of Agendia include EXACT Sciences, DNA Genotek and DNA Diagnostics Center.

  • Where is Agendia headquarters?

    Agendia headquarters is located at 22 Morgan, Irvine.

  • Where are Agendia offices?

    Agendia has offices in Irvine and Amsterdam.

  • How many offices does Agendia have?

    Agendia has 2 offices.